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A platinum-taxane doublet has been established as the standard of care in the initial che-
motherapy for ovarian cancer. Treatment at relapse is based largely on the platinum-free
interval (PFI). Women with a PFI of 6–12 months are said to be partially platinum-sensitive.
Based on the evidence from randomised trials, many clinicians offer treatment to this
group with a platinum-containing doublet (including paclitaxel or gemcitabine). A promis-
ing third option under investigation is the combination of liposomal doxorubicin (PLD) with
carboplatin. However, monotherapy with drugs such as PLD or carboplatin is an accepted
alternative, and treatment is often chosen on an individual basis or because of the avail-
ability of an appropriate clinical study. Extending the PFI by the use of non-platinum mono-
therapy such as PLD at first-relapse may theoretically be helpful, but would need
confirmation in prospective randomised trials.
 2007 Elsevier Ltd. All rights reserved.1. Introduction blet provides a survival advantage compared with carboplatinThe most commonly used initial chemotherapy regimen for
ovarian cancer is a platinum-taxane regimen.1 It is estimated
that approximately 80% of women with ovarian cancer will
relapse and require second-line therapy.2 The choice of sec-
ond-line treatment is typically based on the duration of re-
sponse to the initial platinum-based regimen (i.e. platinum-
free interval or PFI). Response to second-line therapy and
prognosis are also linked to PFI, with both improving as the
PFI increases. Patients with an initial PFI less than 6 months
are described as platinum-resistant. If the disease actually
progresses during treatment (as opposed to relapsing after
treatment discontinuation) it is described as platinum-refrac-
tory. Patients with a PFI greater than 6 months are deemed
platinum-sensitive. Within this group, patients with a PFI of
6–12 months are often considered partially platinum-sensi-
tive. While it is established that a carboplatin-containing dou-er Ltd. All rights reserved
1.monotherapy in patients with platinum-sensitive relapsed
ovarian cancer (ROC),3,4 the extent of that benefit in the
subgroup of partially platinum-sensitive is debatable, and
the management of this subgroup continues to present
challenges.
Because most patients are treated with a platinum-con-
taining regimen at the time of initial diagnosis, the PFI and
RFI (relapse-free interval) at the time of initial relapse are gen-
erally the same. This does not apply when considering further
relapses, when the PFI and the RFI may be quite different. The
clinical relevance is that in relapsed disease, patients deemed
to have platinum-resistant disease at one point may still ben-
efit from platinum at a later time point.
1.1. Agents demonstrating efficacy in partially platinum-
sensitive ROC
1.1.1. Carboplatin
Carboplatin is well tolerated and the response in women with
ovarian cancer relapsing 6–12 months after completion of ini-
.
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30%.4 Because the response rate increases to as high as 60%
or more in women with a PFI of 12 months or more after com-
pletion of previous platinum-based chemotherapy,3,4 it may
be beneficial to defer the use of carboplatin in the 6–12 month
setting. There are non-randomised retrospective data to sup-
port the contention, at least that some patients with plati-
num-resistant disease can regain platinum sensitivity after
intervening treatment with another agent.5,6 However, no
randomised trials of this approach have been reported.
1.1.2. Non-carboplatin options
While carboplatin may be the most frequently used agent in
women with platinum-sensitive ROC (PFI > 6 months),
numerous non-platinum agents have demonstrated compa-
rable activity (Table 1) when used as monotherapy in partially
platinum-sensitive patients. Each agent is associated with a
unique safety profile. Typically, serious adverse events can
be effectively managed; however, there are toxicities that,
while not life-threatening, can be particularly bothersome
(e.g. alopecia). These toxicities should be taken into consider-
ation when selecting the best treatment for a particular
patient.
Randomised phase III data are available for four non-plat-
inum agents in platinum-sensitive ROC: paclitaxel, pegylated
liposomal doxorubicin (PLD), topotecan and gemcitabine.9–14
The trials reporting on paclitaxel versus topotecan9,10 and
PLD versus topotecan11,12 are published in full (Table 2). Trials
reporting on PLD versus paclitaxel 13 and PLD versus gemcit-
abine14 are published in abstract form only and data are
limited.
Paclitaxel was compared with topotecan in 226 women
with ROC; approximately 50% had platinum-sensitive disease
(RFI > 6 months). The objective response rate was higher inTable 1 – Non-platinum agents in ROC7,8






Pegylated liposomal doxorubicin 28
Topotecan 33
Vinorelbine 29
Table 2 – Fully published randomised trials of non-platinum si
cancer




Topotecan (52) 28.8% (P = .213)
Gordon (2001, 2004)7,8 PLD (109) 28.4%
Topotecan (111) 28.8% (P = .964)
NR, not reported.platinum-sensitive patients receiving topotecan, but the dif-
ference was not statistically significant. At long-term follow-
up, paclitaxel was associated with a pronounced survival ben-
efit (significance not reported) in the platinum-sensitive
group. Myelosuppression was the most common adverse
event in both treatment groups, with Grade 4 myelosuppres-
sion reported in 79% of patients receiving topotecan and
23% receiving paclitaxel as second-line therapy and 81% and
23%, respectively, receiving third-line therapy. Grade 4 throm-
bocytopenia was also more common in topotecan-treated pa-
tients.9,10 No results were reported for the subgroup of
patients with partially platinum-sensitive ROC.
Topotecan was compared with PLD in 474 women with
recurrent ovarian cancer. Patients were classified as plati-
num-sensitive (n = 220) if they had a PFI > 6 months after
first-line platinum chemotherapy. The response rates were
nearly identical in both treatment groups, but there was a
superior progression-free survival as well as a statistically sig-
nificant survival benefit in platinum-sensitive patients trea-
ted with PLD (108 versus 70 weeks, p = .017). The survival
benefit was maintained when overall survival was analysed
in the subgroup of partially platinum-sensitive patients with
a PFI of 6–12 months (Fig. 1). No data are available on treat-
ment given to patients on either arm once the disease had
progressed following either PLD or topotecan. It is conceivable
that the difference in overall survival could be partly ex-
plained if subsequent treatment patterns differed, e.g. more
patients on the PLD arm receiving subsequent carboplatin.
While a similar percentage of women in each treatment
group experienced Grades 1, 2 and 3 adverse events, more
topotecan-treated women experienced Grade 4 events
(71.1% versus 17.2%). The most common adverse events in pa-
tients receiving PLD were hand–foot syndrome (HFS) (49%)
and stomatitis (40%). Most HFS was Grades 1–3. Grade 4 HFSToxicity leading to quality of life issues
Hypersensitivity, diarrhoea, fluid retention
Alopecia, GI toxicity
Flu-like constitutional symptoms, hepatic dysfunction, dyspnea
Alopecia, peripheral neuropathy, arthralgias/myalgias
Hand–foot syndrome, mucositis
Asthenia, alopecia, schedule of administration
Constipation, nausea, peripheral neuropathy
ngle-agent therapy of platinum-sensitive relapsed ovarian
Overall survival Comments
85.1 weeks Grade 4 neutropenia:
Paclitaxel = 23% Topotecan = 79–81%63.4 weeks (P  NR)
107.9 weeks Grade 4 adverse events:
PLD = 17.2% Topotecan = 71.1%70.1 weeks (P = .017)
Fig. 1 – Pegylated liposomal doxorubicin (PLD) versus
topotecan. Survival in patients relapsing 6–12 months after
completing first-line platinum-based therapy. (With
permission from Colombo and Gore, 20074.)
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were common with topotecan, with 81% of patients experi-
encing neutropenia, 72% anaemia, 65% thrombocytopenia
and 63% leukopenia. Alopecia was also more common with
topotecan compared with PLD (49% versus 16%).11,15
PLD and paclitaxel were compared in 214 taxane naı¨ve wo-
men with ROC that recurred after or did not respond to first-
line treatment with a platinum-based regimen. The propor-
tion of platinum-sensitive patients was not reported. There
were no statistically significant between-group differences
in objective response rate, progression-free survival (PFS), or
overall survival. When patients were stratified by first-line
platinum response, there were no significant differences in
PFS or overall survival for platinum sensitive patients. While
the number of adverse events was similar in each arm, pa-
tients treated with PLD experienced more nausea, vomiting,
stomatitis and HFS and patients treated with paclitaxel expe-
rienced more alopecia, myalgia, arthralgia and paresthesia.13
The most recent phase III data are for PLD versus gemcit-
abine. Patients had ROC, failed only one line of a platinum-
paclitaxel doublet, and had a PFI of 12 months or less.
Approximately, 50% of patients (78 of 147) had a PFI of 6–12
months. PLD and gemcitabine exhibited similar activity in
the overall population. Data were not presented separately
for the partially platinum-sensitive population. More patients
in the gemcitabine group had Grades 3 and 4 leukopenia (9%
versus 22%; p = .03). There were no statistically significant dif-
ferences in non-haematologic toxicities.14
1.2. Platinum versus non-platinum agent at first relapse
The choice of carboplatin-based or non-carboplatin-based
treatment for partially platinum-sensitive patients is not
straightforward and may best be made on an individual basis.
In addition, the tendency to use a non-carboplatin-based
treatment may be higher if the PFI is 6–8 months, whereas a
carboplatin-based treatment may be favoured if the PFI is10–12 months. Whenever possible, entry into a prospective
randomised trial is the preferred option. The potential benefit
of artificially prolonging the PFI by the use of a non-platinum-
containing regimen at first relapse has been investigated at
MD Anderson Cancer Center5,6 and by the SOCRATES
investigators.16
In two series of patients with a RFI < 6 months, treatment
was initiated with non-platinum agents before retreatment
with platinum. The median PFI when platinum was eventu-
ally given was 15 months and clinical benefit ranged from
39% in the earlier series (1995) to 68% in the most recent series
(1996–2002). All responders had a PFI of at least 12 months5,6
The conclusion to be drawn from these data is that the use of
repeat single-agent carboplatin in platinum-resistant patients
may be justified after treatment with a non-platinum-con-
taining regimen.
In Italy, the SOCRATES investigators conducted a retro-
spective study to determine the impact of extending the PFI
with a non-platinum agent in women with a relapse-free
interval (RFI) of at least 6 months.16 Patients from 37 centres
were treated between 2000 and 2002. Data were available for
428 patients, of whom 40% had a RFI of 6–12 months. A total
of 282 patients received a platinum agent at first relapse after
a median RFI of 19 months and achieved a response rate of
74% (group A). Sixty-seven partially platinum-sensitive pa-
tients (median RFI 9.6 months) achieved a response rate of
45% after treatment with a non-platinum agent. Upon relapse
(median PFI 23 months), these partially platinum-sensitive
patients received a platinum agent and achieved a response
rate of 57% (group B). A second group of 79 partially plati-
num-sensitive patients (median RFI 8.4 months) received
platinum at first relapse and achieved a response rate of only
29% (group C). The difference in response to second-line plat-
inum versus delayed platinum was statistically significant
(p = .02). Median overall survival was similar in patients who
were platinum-sensitive with a RFI > 12 months and patients
who were partially platinum-sensitive (RFI 6–12 months) and
received delayed platinum treatment (27.3 versus 26.1
months). Median overall survival was more than 35% lower
in partially platinum-sensitive patients who received a plati-
num as second-line therapy (16.8 months).16
A prospective randomised trial is warranted to confirm
these findings suggesting that extending the platinum-free
interval may be beneficial in patient with partially plati-
num-sensitive ROC.
1.3. Monotherapy versus combination therapy with
carboplatin
Several platinum-containing doublets have been compared
with monotherapy. The ICON4 AGO OVAR 2.2 phase III trial
compared paclitaxel plus a platinum-based regimen (paclit-
axel plus carboplatin in 80%) with conventional platinum-
based chemotherapy (carboplatin monotherapy in 71%) in
802 women with ROC and a PFI of at least 6 months. The plat-
inum-taxane regimen was associated with an improved re-
sponse rate (66% versus 54%, p = .06), improved PFS (12
months versus 9 months; HR = 0.76, p = .0004), and improved
overall survival (29 months versus 24 months; HR = 0.82,
p = .02). The impact of combination therapy versus conven-
Fig. 3 – Progression-free survival (PFS) in patients with a
platinum-free interval of 6–12 months treated with carbo-
platin alone (Cb) or carboplatin plus gemcitabine (GCb).17
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less in patients with a PFI of 6–12 months compared with
>12 months, but the difference was not statistically signifi-
cant (Fig. 2). The doublet was associated with higher rates of
alopecia and more Grades 2–4 neurological toxicity. Patients
in the carboplatin alone group experienced more moderate
to severe haematologic toxicities.3
The AGO OVAR 2.5 phase III trial randomised 356 patients
with platinum-sensitive disease (PFIP 6 months) to carbo-
platin alone or carboplatin plus gemcitabine. Progression-free
survival was significantly longer in patients receiving carbo-
platin plus gemcitabine (8.6 months versus 5.8 months; HR
0.72; 95% confidence interval (CI) 0.58–0.90, p = .0031).17 Im-
proved PFS was maintained in patients whose PFI was 6–12
months (7.9 months versus 5.2 months; HR 0.69, 95% CI
0.49–0.97; p = .0311) (Fig. 3). In the overall population, response
rate favoured the doublet (47.2% versus 30.9%, p = .0016).
Overall survival was similar in the two groups (18.0 versus
17.3 months) but the study was not powered for an overall
survival end-point. Grades 3 and 4 haematologic toxicity
(anaemia, neutropenia, thrombocytopenia) was significantly
more common in patients receiving the doublet (p < .001).
The incidence of Grade 3 or 4 non-haematologic toxicities
was similar in both groups; however, Grade 2 alopecia was re-
ported in 14.3% of patients receiving the combination and
2.3% receiving carboplatin alone.17
A phase II study evaluating the combination of PLD plus
carboplatin offers additional insight. Of 105 women with
ROC and a PFI of 6 months or more enrolled in the study, 43
had a PFI of 6–12 months. All patients received prior treat-
ment with platinum and a taxane and were receiving second-
or third-line therapy. The objective response rate was 63%.
Median PFS was 9.4 months in the overall population, 11.4
months in patients with a treatment-free interval (TFI) > 12
months, and 7.9 months in patients with a TFI of 6–12 months
(p = .001 for TFI > 12 months versus 6–12 months). A similar
pattern was observed for overall survival, with median sur-Fig. 2 – Overall survival (OS) and progression-free survival
(PFS) in patients treated with a paclitaxel-platinum doublet
(primarily paclitaxel plus carboplatin) versus a conventional
platinum regimen (primarily carboplatin alone) in the ICON4
AGO OVAR 2.2 trial.3vivals of 32 months, 36 months and 21 months, respectively
(p = .006 for TFI > 12 months versus 6–12 months). These re-
sponses and survival data compare favourably with those re-
ported in ICON-4 and the AGO OVAR 2.5 trial, albeit in
different studies. In this phase II trial, the proportions of (less
favourable) patients with a PFI of 6–12 months and more
extensive prior therapy were actually higher than in the two
randomised trials (Table 3). Most non-haematologic toxicity
was Grades 1 or 2. There was limited alopecia (33% Grades 1
and 2) and neurotoxicity (27% Grades 1 and 2, 1% Grade 3)
and no Grade 3 or 4 HFS. Grade 3 or 4 haematologic toxicities
included neutropenia (51%), leukopenia (27%), thrombocyto-
penia (26%), anaemia (12%) and febrile neutropenia (3%).18
In view of these promising data a phase III study has been
initiated to compare the efficacy of a PLD plus carboplatin reg-
imen with that of paclitaxel plus carboplatin (CALYPSO) in pa-
tients with platinum-sensitive ROC (PFI > 6 months). The trial
will shortly complete its accrual target of 800 patients, with
the first analysis expected in late 2008.
2. Discussion and conclusions
At present there are two trials which have been most influen-
tial in formulating policy for treating partially platinum-sen-
sitive ROC. These are the ICON-4 and the AGO-OVAR
gemcitabine trials. In many centres, such patients are now
treated with either paclitaxel–carboplatin or gemcitabine–car-
boplatin. A third option, that of PLD–carboplatin, is also given
regularly, although as yet there are no substantial randomised
data demonstrating equivalence or superiority to paclitaxel–
carboplatin. One randomised trial has been reported, compar-
ing PLD–carboplatin with carboplatin in platinum-sensitive
recurrent ovarian cancer. Although an analysis did suggest
superiority for PLD–carboplatin, the small number of patients
recruited (total of 61) preclude any firm conclusions.19 The re-
sults of the CALYPSO trial will therefore be particularly impor-
tant, since it is quite conceivable that the toxicity profile of
Table 3 – Combination regimens evaluated for second-line therapy in platinum-sensitive patients
Study PLD + carboplatin Paclitaxel + carboplatin Gemcitabine + carboplatin
Ferrero et al. (2007)16 ICON4 AGO OVAR 2.2 Trial3 AGO OVAR 2.5, NCIC and EORTC GCG Trial15
Patient characteristics
Number of patients 105 392 178
% TFI 6–12 months 43% 23% 40%
% TFI >12 months 53% 77% 60%
Prior therapies
% with 1 60% 90% 100%
% with P2 40% 10% 0
% prior taxanes 100% 43% 70%
Efficacy results in total population/patients with 6–12 month TFI
OR (CR) 63% (38%)/NR 66% (NR)/NR 47% (15%)/NR
PFS, median 9.4 months/7.9 months 12 months/NR 8.6 months/7.9 months
OS 32 months/21 months 29 months/NR 18 months/NR
CR, complete response; NR, not reported; OR, objective response; OS, overall survival; PFS, progression-free survival; TFI, treatment-free
interval.
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or gemcitabine–carboplatin given in this context. In partially
platinum-sensitive patients with a PFI approaching 6 month
(i.e. PFI 6–9 months), it may be helpful to prolong the PFI by
the administration of monotherapy with an agent such as
PLD. This strategy may allow for a higher response rate to
subsequent platinum treatment. A phase III study is required
to confirm the benefit of prolonging the PFI by administering a
non-platinum agent at first relapse.
Another possible approach to consider is the introduction
of non-platinum-containing combination regimes. While var-
ious doublets have been assessed, none have been subject to
randomised comparison against a single (non-platinum)
agent. The first such trial involves a new cytotoxic agent –
Yondelis20 and the trial (which includes partially platinum-
sensitive patients with ROC) compares single agent PLD with
a Yondelis-PLD combination. It has recently completed ac-
crual and first results are expected in the near future.
The goal of ROC treatment is no longer just palliation, but
prolonging survival. This is achieved by administering a new
line of chemotherapy at each relapse. An additional approach
may be the administration of maintenance regimens. The se-
lected maintenance regimen should be well tolerated during
long-term therapy. One small trial and a report of three cases
have been published in which PLD was well tolerated when
administered for up to 6 years in women with ROC.21,22 A
maintenance strategy opens up the potential for considering
alternative forms of treatment other than chemotherapy. Tar-
geted agents, particularly those aimed at inhibiting angiogen-
esis through VEGFR inhibition, are particularly attractive in
this context, and a number of trials of this approach are
now underway.
Other novel approaches to the management of partially
platinum-sensitive ROC include resistance modulation based
on the concept that drug resistance (to carboplatin) results
from gene hypermethylation and silencing of damage recog-
nition genes (e.g. hMLH1).23 Data to support this notion have
been provided within the framework of the SCOTROC-1 trial,which involved first-line treatment of ovarian cancer
patients.
When plasma DNA of patients with ovarian cancer was
examined before treatment with carboplatin-taxane chemo-
therapy and again at relapse, the number of patients with
hMLH1 methylation was found to increase. DNA in the plasma
is known to have been shed by tumour; hence, it is a reliable
and important marker for tumour behaviour. Acquisition of
hMLH1 methylation was predictive of poor overall survival.23
In vitro data suggest that methylation of hMLH1 may be asso-
ciated with increased resistance to cisplatin and carboplatin
and that restoration of hMLH1 expression using the demethy-
lating agent, decitabine, increases sensitivity.24 Thus, identifi-
cation of acquired hMLH1 methylation may prove to be helpful
in selecting patients who may derive particular benefit from
demethylation therapies, such as decitabine, to restore plati-
num sensitivity. In the UK, Cancer Research UK is conducting
a clinical trial in which patients with partially platinum-sensi-
tive ROC are randomised to treatment with carboplatin alone
or carboplatin plus decitabine. An earlier phase I trial has con-
firmed the feasibility of the decitabine–carboplatin combina-
tion, and also showed that demethylation did indeed occur
in tumour samples at well tolerated doses.25
In the next few years, a range of randomised clinical trials
will report data which may help in decision making for the
treatment of patients with partially platinum-sensitive ROC.
One which is not yet agreed or underway is the trial which
would answer the question of prolongation of the PFI in order
to increase platinum efficacy. Hopefully this gap will be ad-
dressed by one of the excellent cooperative groups devoted
to the treatment of this disease.Conflict of interest statement
S.B.K. is a member of Advisory Boards for Johnston & Johnston
and Schering Plough and has received honoraria from both
companies.
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